My first question was on the pricing cut. Typically, historically, seeing that across the innovator molecules or the products that we have been working on, what has been the worst-case pricing cut that we would have seen historically?
On the patented CSM side, you did allude towards around 10 %-15% pricing cut that we have seen till now given the product getting generic in some of the key markets globally, earlier experience?